Correa, Denise D. http://orcid.org/0000-0002-7423-8172
Braun, Erica
Kryza-Lacombe, Maria
Ho, Ka-Wai
Reiner, Anne S.
Panageas, Katherine S.
Yahalom, Joachim
Sauter, Craig S.
Abrey, Lauren E.
DeAngelis, Lisa M.
Omuro, Antonio
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 20 June 2019
Accepted: 31 July 2019
First Online: 3 August 2019
Compliance with ethical standards
:
: Dr. Correa serves on the Editorial Board of <i>Neuro-Oncology Practice.</i> Ms. Reiner serves on the Editorial Board of <i>Journal of the National Cancer Institute</i>, <i>Journal of the National Cancer Institute Cancer Spectrum</i>. Dr. Panageas serves on the Editorial Board of <i>Clinical Cancer Research</i>, <i>Journal National of the Cancer Institute</i>, <i>Journal of the National Cancer Institute Cancer Spectrum</i>. She holds stock ownership in Johnson and Johnson, Pfizer, Viking Therapeutics, Catalyst Biotech. Dr. DeAngelis serves on the Editorial Board of <i>Neurology, Journal of Neuro-Oncology, The Open Clinical Cancer Journal, CNS Oncology, Neuro-Oncology, and Neuro-Oncology Practice, and Scientific,</i> and on the Advisory Board of <i>Sapience Therapeutics.</i> Dr. Omuro serves on the Editorial Board of <i>Journal of Neuro-Oncology</i> and <i>Neuro-Oncology Practice,</i> and has consulted for BTG. Dr. Sauter has served as a paid consultant on Advisory Boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite, a Gilead Company and GSK. He has received research funds for investigator-initiated trials from Juno Therapeutics and Sanofi-Genzyme. Dr. Abrey is a full-time employee and shareholder in Novartis. The following co-authors have no conflicts of interest: Ms. Braun, Ms. Kryza-Lacombe, Dr. Yahalom, and Dr. Ka-Wai Ho.